166 related articles for article (PubMed ID: 30019187)
1. A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.
Jacob TF; Singh V; Dixit M; Ginsburg-Shmuel T; Fonseca B; Pintor J; Youdim MBH; Major DT; Weinreb O; Fischer B
Purinergic Signal; 2018 Sep; 14(3):271-284. PubMed ID: 30019187
[TBL] [Abstract][Full Text] [Related]
2. Purinergic dysregulation causes hypertensive glaucoma-like optic neuropathy.
Shinozaki Y; Kashiwagi K; Namekata K; Takeda A; Ohno N; Robaye B; Harada T; Iwata T; Koizumi S
JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978804
[TBL] [Abstract][Full Text] [Related]
3. Hypotensive effect of UDP on intraocular pressure in rabbits.
Markovskaya A; Crooke A; Guzmán-Aranguez AI; Peral A; Ziganshin AU; Pintor J
Eur J Pharmacol; 2008 Jan; 579(1-3):93-7. PubMed ID: 18031728
[TBL] [Abstract][Full Text] [Related]
4. 5-OMe-uridine-5'-O-(α-boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y(6) receptor protects against death-receptor mediated glial apoptosis.
Haas M; Ginsburg-Shmuel T; Fischer B; Reiser G
Neurosci Lett; 2014 Aug; 578():80-4. PubMed ID: 24970757
[TBL] [Abstract][Full Text] [Related]
5. Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits.
Martin-Gil A; de Lara MJ; Crooke A; Santano C; Peral A; Pintor J
Br J Pharmacol; 2012 Feb; 165(4b):1163-72. PubMed ID: 21740413
[TBL] [Abstract][Full Text] [Related]
6. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
[TBL] [Abstract][Full Text] [Related]
7. The 5-HT(1A)Receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits.
Chidlow G; Nash MS; De Santis LM; Osborne NN
Exp Eye Res; 1999 Dec; 69(6):587-93. PubMed ID: 10620387
[TBL] [Abstract][Full Text] [Related]
8. UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety.
Ginsburg-Shmuel T; Haas M; Grbic D; Arguin G; Nadel Y; Gendron FP; Reiser G; Fischer B
Bioorg Med Chem; 2012 Sep; 20(18):5483-95. PubMed ID: 22901672
[TBL] [Abstract][Full Text] [Related]
9. Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma.
Crooke A; Huete-Toral F; Martínez-Águila A; Martín-Gil A; Pintor J
J Pharmacol Exp Ther; 2013 Jul; 346(1):138-45. PubMed ID: 23591996
[TBL] [Abstract][Full Text] [Related]
10. Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma.
Fonseca B; Martínez-Águila A; de Lara MJP; Pintor J
Purinergic Signal; 2017 Jun; 13(2):171-177. PubMed ID: 27848070
[TBL] [Abstract][Full Text] [Related]
11. The pyrimidinergic P2Y6 receptor mediates a novel release of proinflammatory cytokines and chemokines in monocytic cells stimulated with UDP.
Cox MA; Gomes B; Palmer K; Du K; Wiekowski M; Wilburn B; Petro M; Chou CC; Desquitado C; Schwarz M; Lunn C; Lundell D; Narula SK; Zavodny PJ; Jenh CH
Biochem Biophys Res Commun; 2005 May; 330(2):467-73. PubMed ID: 15796906
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
[TBL] [Abstract][Full Text] [Related]
13. 2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.
Eliahu S; Martín-Gil A; Perez de Lara MJ; Pintor J; Camden J; Weisman GA; Lecka J; Sévigny J; Fischer B
J Med Chem; 2010 Apr; 53(8):3305-19. PubMed ID: 20337495
[TBL] [Abstract][Full Text] [Related]
14. Central Role of P2Y6 UDP Receptor in Arteriolar Myogenic Tone.
Kauffenstein G; Tamareille S; Prunier F; Roy C; Ayer A; Toutain B; Billaud M; Isakson BE; Grimaud L; Loufrani L; Rousseau P; Abraham P; Procaccio V; Monyer H; de Wit C; Boeynaems JM; Robaye B; Kwak BR; Henrion D
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1598-606. PubMed ID: 27255725
[TBL] [Abstract][Full Text] [Related]
15. Changes in P2Y Purinergic Receptor Expression in the Ciliary Body in a Murine Model of Glaucoma.
Fonseca B; Martínez-Águila A; Pérez de Lara MJ; Miras-Portugal MT; Gómez-Villafuertes R; Pintor J
Front Pharmacol; 2017; 8():719. PubMed ID: 29085298
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.
Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329
[TBL] [Abstract][Full Text] [Related]
17. Sp-2-propylthio-ATP-α-B and Sp-2-propylthio-ATP-α-B,β-γ-dichloromethylene are novel potent and specific agonists of the human P2Y₁₁ receptor.
Haas M; Ben-Moshe I; Fischer B; Reiser G
Biochem Pharmacol; 2013 Sep; 86(5):645-55. PubMed ID: 23810430
[TBL] [Abstract][Full Text] [Related]
18. Ocular hypotensive effects of anti-glaucoma agents in mice.
Akaishi T; Odani-Kawabata N; Ishida N; Nakamura M
J Ocul Pharmacol Ther; 2009 Oct; 25(5):401-8. PubMed ID: 19857101
[TBL] [Abstract][Full Text] [Related]
19. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
20. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
